Background: Rifaximin reduces the risk of overt hepatic encephalopathy (HE) and is
| MATERIAL S AND ME THODS

| Study design and setting
The patient records of 622 patients with confirmed cirrhosis (the diagnosis of cirrhosis was confirmed by a combination of a least 2 modalities: clinical, biochemical, radiological and histopathological) who were listed for liver transplantation at King's College Hospital NHS Foundation Trust over a 2-year period [1st January 2014 -31st
January 2016] were retrospectively reviewed.
| Participants
Patients were included if they had at least two historic episodes of overt HE resulting in hospitalisation or were overtly encephalopathic at the time of assessment. Patients under the age of 18 were excluded from the study.
| Data collection
Information collected included patient demographics, aetiology of liver disease, Child Pugh Turcotte score, 12 Model for End-stage Liver Disease (MELD) score 13 at the time of assessments, United Kingdom
End-stage Liver Disease (UKELD) score, maximum grade of HE (defined using the West Haven criteria), 14 blood ammonia concentration (venous), concurrent lactulose therapy, medical co-morbidities, emergency admission whilst on the waiting list including admissions to high dependency and intensive care beds, requirement for prioritisation (UKELD score ≥63), duration on the waiting list (days) and mortality on the waiting list. Elective admissions, such as for large volume paracentesis were excluded unless the paracentesis was complicated (defined as necessitating a hospital admission for greater than 24 hours) which may occur for example due to spontaneous bacterial peritonitis, acute kidney injury or electrolyte disturbance.
| Statistical methods
The primary outcome was defined as the number of days to all cause readmission on the transplant waiting list. Forward selection was used to select independent variables within the regression models with P < 0.1; we also included variables considered by subject knowledge or literature (ie lactulose use and MELD score) to be associated with hospital readmission in endstage chronic liver disease. Univariate and regression analyses were performed using IBM spss Statistics 24 for Mac. A P < 0.05 was considered to be statistically significant.
| RE SULTS
| Patient demographics
Of the 622 adult patients listed for transplantation, 101 were listed with HE. Sixty-six patients were treated with rifaximin and 35 were naïve. There was a male preponderance in both groups and alcohol-related liver disease was the most common aetiol- 
| Clinical outcomes
On univariate analysis, rifaximin-treated patients had reduced allcause admissions (elective admissions were excluded) on the waiting Table 2 and Figure 1 .
Multivariate linear regression analysis with days to readmission (related to complications of ascites, variceal bleeding, hepatic encephalopathy or sepsis) defined as the dependent variable demonstrated that rifaximin treatment was independently associated with increased length to all-cause readmission whilst on the liver transplant waiting list; adjusted effect estimate 71 (95% CI 3-140 days)
when adjusting for age, sex, BMI, disease severity score and concomitant lactulose use. Similarly, rifaximin use was independently 
| D ISCUSS I ON
This retrospective 'real-world' cohort study examining the liver transplant waiting list outcomes of 101 patients listed with overt HE shows that those who were prescribed rifaximin for the recurrence of overt HE had improved outcomes on the waiting list with a significant reduction in all-cause hospital admissions, an increased time to hospital readmission and reduced requirement for listing prioritisation compared to those naïve to rifaximin.
There is now a robust evidence base to support rifaximin as a beneficial adjunctive therapy to lactulose in the prevention of re- score of ≤10, two-thirds with a MELD score between 11 and 18 and <10% with a MELD between 19 and 24. We therefore set out to determine the impact of treatment with rifaximin in patients listed with overt HE whilst they were on the liver transplant waiting list at a large UK transplant centre.
One of the strengths of this study was that whilst a large proportion of the patients included in this study had alcohol-related cirrhosis because they had been abstinent for at least 6 months prior to listing, active alcohol intake was not a confounder in this study as it has been in other 'real-world' studies 10, 11 where it was difficult to determine if abstinence from alcohol or rifaximin was the major driver in the improved outcomes in this cohort of patients.
Patients with advanced cirrhosis are susceptible to unplanned emergency hospitalisations for a variety of reasons, including susceptibility to infection, 17 overt HE, 5 acute kidney injury, acute variceal bleeding, electrolyte disturbance, large volume ascites, spontaneous bacterial peritonitis, falls, malnutrition and sarcopenia.
These patients frequently progress to requiring high dependency or intensive care support 2, 18 and may at any time progress to developing ACLF. 19, 20 Infection is the leading cause of death in patients with end-stage liver disease and confers a fourfold increased mortality compared to non-infected patients; 30% of patients die within 1 month after infection and another 30% die by 1 year with spontaneous bacterial peritonitis and urinary tract infections representing the commonest bacterial infections complicating cirrhosis. 21 Systemic inflammation and infection are also major drivers of episodes of HE 22, 23 and have been implicated in patients admitted with advanced HE (grades 3 and 4) regardless of blood ammonia levels and MELD score.
24
Systemic inflammation is also likely to be the single biggest driver for the development of ACLF. In the CANONIC study patients with acute decompensation of cirrhosis without ACLF showed very high baseline levels of inflammatory cytokines, markers of systemic oxidative stress and circulatory dysfunction. Moreover, patients with ACLF showed significantly higher levels of these markers than those without ACLF. 25 It therefore follows that if patients in this study treated with rifaximin have reduced all-cause unplanned hospitalisations and episodes of spontaneous bacterial peritonitis that rifaximin is reducing systemic inflammation and/or the susceptibility to developing infection. 26 Indeed, it has been shown that rifaximin does reduce systemic endotoxin levels and this is likely to be linked to a change in the function rather than composition of the gut microbiome which we know exhibits dysbiosis in patients with advanced cirrhosis. 8, 27 Indeed, a recent systematic review and meta-analysis examining the impact of rifaximin on the development of spontaneous bacterial peritonitis showed that rifaximin may be effective in preventing spontaneous bacterial peritonitis in patients with cirrhosis and ascites compared to systemically absorbed antibiotics and compared to placebo. 9 Another retrospective study examining 145 patients with cirrhosis showed rifaximin treatment was significantly associated with prolonged overall survival and reduced risks of spontaneous bacterial peritonitis, variceal bleeding and recurrent HE. 28 A further randomised study of rifaximin vs placebo also showed that rifaximin prevented the development of hepatorenal syndrome which in many cases develops in association with spontaneous bacterial peritonitis. in the naïve group) and patients listed for liver transplantation for HE invariably had severe and treatment-refractory encephalopathy. It is also important to say that patients with admissions for falls, sepsis and bleeding often developed HE during that admission so a reduction in all-cause admissions on rifaximin indirectly reduced the likelihood of developing HE. There was also no difference in mortality although overall the transplant waiting list mortality in this cohort was low at 13.89% so more patients would need to have been included to detect a mortality difference. Nevertheless, patients who deteriorate whilst on the waiting list may require prioritisation (in this study this was when their UKELD score reached 63 or above).
Patients treated with rifaximin were less likely to require the need for prioritisation in this study and therefore this may have also had a bearing on any perceivable mortality difference. Where this study falls short, however, is that we were unable to determine in many cases the precise duration of rifaximin therapy prior to being referred and listed for transplantation as many patients were tertiary referrals from other centres where we could not access this infor- with rifaximin was associated with a reduction in length of hospital stay and provides good value for money in terms of health economics and resource utilisation. 10, 11 In summary, rifaximin prescribed for the recurrence of overt HE in patients listed for liver transplantation improved outcomes on the waiting list with a significant reduction in hospital admissions related to decompensation, variceal bleeding and complications of ascites.
There was a reduced requirement for prioritisation of patients on the waiting list in patients treated with rifaximin and an increased time to hospital readmission. This study provides 'real-world' data that demonstrates the potential value of rifaximin in reducing hospital admissions and length of stay within the advanced cirrhotic population awaiting liver transplantation. At this point, however, the data should not be interpreted as a reason to change clinical practice but should act as a catalyst for further prospective studies in this patient group. 
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